Navigation Links
Clinical study shows biological and clinical activity in relapsed leukemia patients
Date:6/4/2008

LUGANO, SWITZERLAND, June 4, 2008 Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML). The promising interim results from this ongoing clinical trial indicate that single-agent GCS-100 induces apoptosis (programmed cell death) in patients' CLL cells, reduces leukocyte count in some patients and is generally well tolerated. GCS-100 targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis.

The ongoing Phase 2 single-arm study of GCS-100 given intravenously as a single agent to relapsed CLL patients is designed to evaluate the effects of GCS-100 on various markers of apoptosis and to assess clinical activity and safety. Patients enrolled have had between one and two prior therapy regimens, which included chlorambucil, fludarabine, cyclophosphamide, and rituximab in combination or as a single agent. Of the nine patients enrolled to-date, six are evaluable for biological marker activity and five are evaluable for clinical activity.

The primary objective of the study is to evaluate the effect of GCS-100 on biomarkers of apoptosis in patients' CLL cells. Caspases -8 and -9 were activated in the CLL cells from all six evaluable patients, as measured by western blot analysis. DNA fragmentation in patients' CLL cells also was observed, strengthening the evidence that GCS-100 induces apoptosis.

The secondary objective of the study is to evaluate the effect of GCS-100 on peripheral blood leukocyte counts, which are aberrantly elevated in CLL patients. Of the five evaluable patients, two had significant reductions in leukocyte counts compared with baseline levels, including one with a 76% reduction and another with a 42% reduction and
'/>"/>

Contact: Michelle Linn
linnmich@comcast.net
508-362-3087
Linnden Communications
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Roughly four in ... obstructive pulmonary disease (COPD) actually do not have the ... issue: Faulty diagnoses were made based on an evaluation ... "gold standard" disease test known as spirometry, which shows ... the amount of air they can exhale and how ...
(Date:5/22/2013)... New research from Brigham and Women,s Hospital (BWH) finds ... uncommon but deadly lung disease, may be effective in ... findings will be presented at the American Thoracic Society ... New England Journal of Medicine on May 22 ... edition., "While this variant of the MUC5B gene is ...
(Date:5/22/2013)... ATS 2013, PHILADELPHIA ─More than 40 percent of ... funded clinic did not have the disease, researchers ... diagnostic "gold standard" for chronic obstructive pulmonary disease. ... the under-diagnosis of COPD, there has not been ... of over-diagnosis," said Christian Ghattas, MD., MSc, ...
(Date:5/22/2013)... In the past decade, more ... courts with donated uniforms, shoes, balls and other ... to partnering with manufacturers to provide youth with sporting ... $8.8 million in sports and fitness equipment over 10 ... outfitted for physical activity. , An inaugural donation ...
(Date:5/22/2013)... Alabama (PRWEB) May 22, 2013 ... solutions to state Health and Human Services and ... of Mental Health (ADMH) selected the CoCENTRIX ... platform to manage the Health Records and coordinate ... psychiatric hospitals. , CoCENTRIX is transitioning the ...
Breaking Medicine News(10 mins):Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Study finds COPD is over-diagnosed among uninsured patients 2Health News:Study finds COPD is over-diagnosed among uninsured patients 3Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3
... salon to help San Diego,s frantic families rid themselves of lice ... the head lice helpers, ( www.hairfairies.com ) today announced that it ... San Diego on May 12, 2009. , , ... salon dedicated to removing head lice. With salons in New ...
... May 12 Blue Cross and Blue Shield of ... an accreditation status of "Excellent" for its HMO products ... is an independent, non-profit organization that evaluates how well ... system -- physicians, hospitals, other providers and administrative services ...
... Manage Their Daily and Weekly MedicationsLAWRENCE, Mass., May 12 ... healthcare industry as a whole, it,s individual healthcare professionals ... a smaller scale.Goss, a medical technologist, enjoys her line ... good about what I do in the hospital lab," ...
... N.H., May 12 After very successful test marketing ... has begun selling its all-natural sports mints called Muscle ... and several electrolytes in a chewable mint, it is ... ingredients are used, and this is reflected in its ...
... PhD, FNP Join Together to Raise Awareness of Common, ... Fibromyalgia is often called an "invisible" illness because ... sick. However, something as simple as a hug ... fibromyalgia is one of the most common chronic, widespread ...
... Evidence-based, Unbiased Determinations Use Latest Clinical InformationLANSDALE, Penn., ... today equals 17 percent of the U.S. gross ... will equal 20 percent. Most politicians and healthcare ... inefficiencies, inflated prices, poor management and waste that ...
Cached Medicine News:Health News:Lice Removal Salon Offers San Diego an Upscale Solution to an Undesirable Problem 2Health News:NCQA Accreditation Status of Excellence Awarded to Blue Cross and Blue Shield of Georgia 2Health News:Healthcare Professional Is Working to Make a Difference, One Dose at a Time 2Health News:New Class of Sports Nutrition Product Launched 2Health News:VIDEO from Medialink, the National Fibromyalgia Association and Pfizer: The Painful Truth about Fibromyalgia 2Health News:IROs Help Cut Health Plan Costs During the Recession 2
(Date:5/22/2013)... 22, 2013  Grifols, a global healthcare company based ... from a study demonstrating that a higher dose of ... levels of the alpha 1 protein in patients ... are considered within the normal range for healthy individuals. ... low levels of the alpha 1 proteinase inhibitor ...
(Date:5/22/2013)...  BD (Becton, Dickinson and Company) (NYSE: ... today the publication of its 2012 Sustainability Report ... continues to focus on the Company,s shared value approach ... of shared value — creating value for shareholders by ... are fundamental to our strategy," said Vincent ...
(Date:5/22/2013)... Calif. , May 22, 2013 Rigel ... the clinical advancement of three programs in development. The ... a JAK/SYK inhibitor, R348, being developed by Rigel as ... programs are aimed at oncology targets and are being ... under development by BerGenBio AS (BerGenBio) and a ligase ...
Breaking Medicine Technology:Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
... PTC Therapeutics, Inc. (PTC) today announced the appointment of ...  Dr. Spiegel served previously as Chief Medical Officer of ... Barth, M.D. to Vice President of Clinical Development.   ... report to Stuart W. Peltz, Ph.D., President and CEO ...
... -- Winner Medical Group Inc. (Nasdaq: ... medical dressings, medical disposables and non-woven fabric made ... announced that Mr. Jianquan Li, Winner Medical,s founder, ... the Distinguished Contribution award for 2010 by the ...
Cached Medicine Technology:PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 2PTC Therapeutics Appoints Robert Spiegel, M.D. as Chief Medical Officer 3Winner Medical CEO Awarded and Appointed Position by CNITA 2Winner Medical CEO Awarded and Appointed Position by CNITA 3Winner Medical CEO Awarded and Appointed Position by CNITA 4
... the serum tube is specially coated with ... coagulation process. Serum / gel tubes contain ... the tube; during centrifugation, this gel forms ... the blood cells. In the primary tube ...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
Medicine Products: